Molecular Hydrogen Mitigates Performance Decrement during Repeated Sprints in Professional Soccer Players.
Michal Botek, Deepesh Khanna, Jakub Krejčí, Michal Valenta, Andrew McKune, Barbora Sládečková, Iva Klimešová · Nutrients · 2022
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In 15 participants, sprint time at 30 m also significantly improved by 1.9% in the HRW group in the last sprint. These findings add human evidence supporting molecular hydrogen's therapeutic potential to influence fatigue-related outcomes.
What the Findings Mean
H2HUBB reviewed how hydrogen-rich water affected the outcomes measured in 15 participants. Sprint time at 30 m also significantly improved by 1.9% in the HRW group in the last sprint.
What the Researchers Studied
The researchers studied 15 participants. The study used a randomized, double-blind, placebo-controlled, crossover human clinical trial. The comparison condition was placebo.
What Effects Did Molecular Hydrogen Have?
Source-reported hydrogen concentration: 0.0 mg/L H₂; Source-reported hydrogen exposure: 420 mL hydrogen-rich water per reported dose; approximately 0 mg H₂ per reported serving. Sprint time at 30 m also significantly improved by 1.9% in the HRW group in the last sprint. The authors concluded that intermittent, acute, pre-exercise HRW consumption with a total dose of 1260 mL caused an approximate 3.1% and 1.9% gain in 15 and 30 m sprint performance, especially during later stages of an experimental 15 × 30 m sprint protocol in professional soccer players.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential to influence fatigue-related outcomes and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a randomized, double-blind, placebo-controlled, crossover human clinical trial. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was 15 participants. The reported sample size was 15. The study used a randomized, double-blind, placebo-controlled, crossover human clinical trial. The hydrogen delivery method was hydrogen-rich water. The source-reported hydrogen concentration was 0.0 mg/L H₂. The source-reported hydrogen exposure was 420 mL hydrogen-rich water per reported dose; approximately 0 mg H₂ per reported serving.
Limitations and Safety
Reported limitations: There are some limitations associated with this study, as follows. (a) The dosage of H₂ was constant per participant and was not adjusted to body mass. (b) Sprint times were not measured using a system with several photocells, which would allow a more detailed assessment of the acceleration phase in repeated sprints. (c) Blood lactate concentrations were not analyzed in duplicate. (d) The oxidative stress response and oxygen consumption during the repeated sprints were not determined.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.